FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

Products, services, technology

We are currently developing antibody-drug conjugates to target high unmet need oncology indications.

We also have pre-clinical, best in class antibodies to address allergy/asthma indications.

Cooperation possibilities

We are always looking for partners to accelerate and de-risk the development of our oncology and immunology antibody-based therapeutics.

We are also raising Series A and as such looking for investors in our company.

Some insights
Additional address info
  • c/o Swiss Innovation Park Basel Area AG
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland

You may also be interested in